TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Trial Details

NCT ID

NCT05901428

Phase

PHASE3

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

Docetaxel
Carboplatin
Epirubicin
Cyclophosphamide

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Women aged 18-70
Unilateral invasive carcinoma confirmed by histology (regardless of pathological type)
The initial diagnosis condition can be directly operated, without absolute surgical contraindications
No gross or microscopic tumor remains after surgical resection

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →